Remove Clinical Trials Remove Environment Remove Safety
article thumbnail

Press Release: Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Cannabis Law Report

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

article thumbnail

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. Forward-looking statements are only predictions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MAPS: Regulatory Publishing Specialist – Remote Position Regulatory Affairs · Any City, Any State, California

Cannabis Law Report

MAPS PBC strives to continually improve upon the supportive, equitable and accessible work environment. The RPS must enjoy working within a small, entrepreneurial environment in which the ability to work under pressure and to handle a wide variety of activities is necessary. Experience working for a clinical study Sponsor.

article thumbnail

Do you trust your doctor about cannabis?

The Cannigma

The dualistic narratives of cannabis reflect the lack of a dominant narrative environment that supports the integration of cannabis into medical practice.”. The paper concluded that the “lack of a dominant narrative environment” on the efficacy of medical marijuana can represent a barrier to the implementation of medical cannabis policies.

Education 105
article thumbnail

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Cannabis Law Report

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. President, Director and Chief Medical Officer of MyMD. “We

article thumbnail

Position: Atai – Director/Manager Regulatory Affairs (f/m/d)

Cannabis Law Report

A fast-paced environment where you’ll work on a wide range of topics. Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. Position: Full-time. Opportunity.

article thumbnail

CBD is Everywhere – But Where Does the FDA Stand?

The Blunt Truth

CBD is “thriving” in the current regulatory environment, but is it doing so illegally? On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. As former U.S. The FDA needs to act.”

CBD 80